Home

 

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

Deloitte Technology Fast 50 Award 2017

ITM as Front-Runner in the Life Sciences Industry of the Germany’s fastest growing Technology Companies

View details >>

December 06, 2017

First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin®)

Full releases >>

November 14, 2017

Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

Full releases >>

November 09, 2017

ITM as Front-Runner in the Life Sciences Industry of the Germany’s fastest growing Technology Companies

Full releases >>

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>